Skip to main content
SpringerLink
Log in

Comment on: “CYP3A4*22 Genotype‑Guided Dosing of Kinase Inhibitors in Cancer Patients”

  • Letter to the Editor
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

The Original Article was published on 13 June 2023

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. van Eerden RAG, Ijzerman NS, van Meekeren M, Oomen-de Hoop E, Guchelaar NAD, Visser AMW, et al. CYP3A4*22 genotype-guided dosing of kinase inhibitors in cancer patients. Clin Pharmacokinet. 2023;62(8):1129–39.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Westra N, Touw D, Lub-de Hooge M, Kosterink J, Oude MT. Pharmacokinetic boosting of kinase inhibitors. Pharmaceutics. 2023;15(4):1149.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Johnson FM, Agrawal S, Burris H, Rosen L, Dhillon N, Hong D, et al. Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. Cancer. 2010;116(6):1582–91.

    Article  CAS  PubMed  Google Scholar 

  4. US FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021986s7s8lbl.pdf. Accessed 28 Dec 2023.

  5. US FDA. https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers#table2-2. Accessed 28 Dec 2023.

  6. Miura M. Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia. Biol Pharm Bull. 2015;38(5):645–54.

    Article  CAS  PubMed  Google Scholar 

  7. Wang X, Roy A, Hochhaus A, Kantarjian HM, Chen TT, Shah NP. Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a Phase III study. Clin Pharmacol. 2013;5:85–97.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Rousselot P, Mollica L, Guilhot J, Guerci A, Nicolini FE, Etienne G, et al. Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients. Br J Haematol. 2021;194(2):393–402.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen and University of Groningen, P.O. Box 30.001, 9700 RB, Groningen, The Netherlands

    Thijs H. Oude Munnink & Daan J. Touw

  2. Department of Hematology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

    Saskia K. Klein

Authors
  1. Thijs H. Oude Munnink
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Saskia K. Klein
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daan J. Touw
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thijs H. Oude Munnink.

Ethics declarations

Funding

Not applicable.

Conflict of interest

The authors declare no potential conflicts of interest.

Informed consent

The patient has consented to the submission of the case report to the journal.

Author contributions

T.H.O.M drafted the manuscript and S.K.K. and D.J.T. revised the draft.

Data availability

Not applicable.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Oude Munnink, T.H., Klein, S.K. & Touw, D.J. Comment on: “CYP3A4*22 Genotype‑Guided Dosing of Kinase Inhibitors in Cancer Patients”. Clin Pharmacokinet (2024). https://doi.org/10.1007/s40262-024-01380-5

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s40262-024-01380-5

Search

Navigation